ZLAB/ 05/11/2026 · 9:31 AM Zai Lab’s Zoci Wins U.S. FDA Fast Track Designation for Aggressive Rare Cancer (epNECs) Zai Lab’s drug Zoci got FDA Fast Track for rare cancer epNEC, showing 38% tumor response in early trials, speeding approval path.